A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Dementia; Lewy body disease; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 13 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
    • 13 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.
    • 13 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top